Approvals in 2016: questioning the clinical benefit of anticancer therapies
Ces articles analysent le rapport coût-efficacité des inhibiteurs de points de contrôle immunitaire, notamment les anticorps anti PD-1 et anti PD-L1, approuvés par la FDA en 2015 et 2016 dans le traitement des cancers
Patients with cancer expect to derive a meaningful clinical benefit from anticancer treatments, especially considering that such therapies are associated with adverse events and, often, substantial financial costs. We have evaluated new anticancer agents approved by the FDA in 2015 and 2016 using the ESMO Magnitude of Clinical Benefit Scale and ASCO Value Framework, and conclude that many agents only offer marginal value.